Scarica l'app Stockscreener
139.34
3.82%
-5.54
Dopo l'orario di chiusura:
139.09
-0.25
-0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RGEN Giù?
Forum
Previsione
Repligen Corp Borsa (RGEN) Ultime notizie
PNC Financial Services Group Inc. Sells 262 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp director Hunt Anthony sells $4.08 million in stock By Investing.com - Investing.com South Africa
Repligen Corp director Hunt Anthony sells $4.08 million in stock - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth and valuation challenges - Investing.com
Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI - Defense World
Repligen Co. (NASDAQ:RGEN) Shares Sold by Victory Capital Management Inc. - Defense World
Repligen director Pax Margaret acquires $37,672 in common stock By Investing.com - Investing.com Australia
REPLIGEN Director Margaret Pax Acquires 250 Shares - TradingView
Evercore ISI sets Repligen stock In Line with $155 price target - Investing.com
Demystifying Repligen: Insights From 6 Analyst Reviews - Benzinga
Repligen initiated with an In Line at Evercore ISI - TipRanks
Repligen Corp (RGEN) Shares Up 5.72% on Mar 17 - GuruFocus.com
Repligen Corp (RGEN) Shares Up 5.72% on Mar 15 - GuruFocus.com
REPLIGEN CORP SEC 10-K Report - TradingView
William Blair Brokers Reduce Earnings Estimates for Repligen - Defense World
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack - The Globe and Mail
Oppenheimer & Co. Inc. Purchases New Shares in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corporation’s Acquisition of Bioprocessing PAT Device Portfolio from 908 Devices - Global Legal Chronicle
US Bancorp DE Raises Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen buying 908 Devices’ Bioprocess Analytics portfolio - BioWorld Online
Sanctuary Advisors LLC Sells 268 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Truist Financial Corp Trims Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - AOL
Leerink maintains Repligen stock Outperform rating, $200 target - Investing.com
908 Devices stock jumps on Repligen deal (RGEN:NASDAQ) - Seeking Alpha
Repligen acquires 908 Devices’ desktop bioprocessing tech - Investing.com
Repligen acquires 908 Devices’ desktop bioprocessing tech By Investing.com - Investing.com Canada
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Yahoo Finance
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Global Retirement Partners LLC Has $53,000 Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Global Hollow Fiber Filtration Market: A Comprehensive Study - openPR
CIBC Asset Management Inc Acquires 81 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Principal Financial Group Inc. Decreases Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen’s SWOT analysis: bioprocessing leader’s stock poised for growth - Investing.com
Repligen stock holds steady after Benchmark maintains rating - Investing.com
Repligen stock holds steady after Benchmark maintains rating By Investing.com - Investing.com UK
Repligen (NASDAQ:RGEN) Price Target Raised to $200.00 - Defense World
Repligen (NASDAQ:RGEN) Price Target Raised to $205.00 - Armenian Reporter
Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Repligen (NASDAQ:RGEN) Earns Buy Rating from HC Wainwright - Defense World
Repligen (NASDAQ:RGEN) Shares Up 8.1% Following Strong Earnings - Defense World
Repligen Earnings: Encouraging Guidance Supports Attractive Growth Story - Morningstar
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Repligen (RGEN) Beats Q4 Earnings Estimates - MSN
Repligen's Q4 Earnings Beat Estimates, Revenues In Line - Yahoo Finance
The Analyst Verdict: Repligen In The Eyes Of 4 Experts - Benzinga
H.C. Wainwright maintains Buy on Repligen, target at $180 - Investing.com
Repligen Corporation (NASDAQ:RGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Canaccord raises Repligen stock target to $170, maintains Hold - Investing.com
KeyBanc maintains Repligen stock with $220 target following Q4 results - Investing.com
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Repligen: Q4 Earnings Snapshot - mySA
Repligen earnings beat by $0.03, revenue topped estimates - Investing.com
What To Expect From Repligen Corp (RGEN) Q4 2024 Earnings - GuruFocus.com
Repligen stock target raised to $165 by Jefferies, retains hold - Investing.com
Repligen's Resurgence: Revolutionary Strides in Bioprocessing Signal Robust Growth Prospects - Elblog.pl
Repligen stock rises on positive Q4 results and 2025 outlook - Investing.com
Unlocking Bioprocessing Success: Repligen’s Market-Defying Momentum - Bit Perfect Solutions
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook - Benzinga
2.34%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):